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Ovarian cancer represents the fifth most frequent cause of death as a result of
malignant processes after cancers of the breast, large intestine, lung and stom-
ach. Owing to the localisation of ovarian cancer, approximately 75% of cases
are diagnosed at the III and IV stages of advancement according to FIGO. Be-
cause of the advanced stage of the disease surgery has to be followed by che-
motherapy in most cases of ovarian cancer and therefore resistance to cytostatic
drugs represents a major clinical problem. The potential to predict the response
to therapy with the use of cytostatic drugs would enable the most effective
drugs to be applied in individual cases, thus improving the efficiency of the
treatment and restricting the development of resistance to cytostatic drugs. In
the present paper the progress made so far in the prediction of the clinical
course of ovarian cancer is reviewed. The significance of the expression of the
ATP-binding cassette (ABC) transporters is described, including P-glycoprotein
and MRP2, the principal representatives of the protein group. The importance
of disturbed control of apoptosis and the overexpression of HER-2 and topoi-
somerase 1A are also discussed. Two sections are devoted to the most recent
studies in the biology of ovarian cancer, pangenomic studies on gene expres-
sion using DNA microarrays and aberrations of DNA methylation.
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INTRODUCTION
Owing to the localisation of ovarian cancer, ap-
proximately 75% of cases are diagnosed at the stag-
es III and IV of advancement according to FIGO. In
such advanced cases only about 20% of patients sur-
vive for 5 years. Because of the advanced stage of
the disease surgery has to be followed by chemo-
therapy in most cases of ovarian cancer. Despite the
introduction of novel chemotherapy regimens, the
five-year survival rate of patients at all clinical stages
has not risen beyond 40% in the last 20 years [3, 7].
Resistance of ovarian cancer cells to cytostatic drugs
represents the principal cause of therapeutic failure
and, consequently, the principal cause of death in
cases of ovarian cancer.
ATP-BINDING CASSETTE (ABC)
TRANSPORTERS
The phenomenon of multidrug resistance (MDR)
was described for the first time at the end of the
1980s [13]. At the time it was demonstrated in in
vitro studies that the development of resistance to
one antineoplastic agent resulted in a cross-resis-
tance to several other cytostatic drugs which were
not inter-related. The principal causes of MDR
in cancer cells are proteins from the group of
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ATP-binding cassette (ABC) transporters, the mem-
branous ATP-dependent pumps, including P-glyco-
protein, MRPs and BCRP proteins [13, 14].
P-glycoprotein (P-gp)
P-glycoprotein (P-gp) is a member of the family of
ABC-transporter proteins. P-gp is an energy-dependent
pump, which in physiological conditions is manifested
in the cell membranes of, for example, hepatocytes
and the cells of renal tubules and is responsible for the
transportation of various substances out of the cell. In
tumours P-gp actively eliminates cytostatic drugs, and
overexpression of P-gp is linked to resistance to cyto-
static drugs [13, 14, 62]. P-gp is composed of two parts
of a similar structure, each containing a hydrophobic
and a hydrophilic part. The hydrophobic part encom-
passes three loops, which span the cell membrane at
six sites. The six transmembrane domains form a canal
through which substances can cross the cell membrane.
The hydrophilic part, located on the cytosolic aspect of
the membrane, contains potential ATP nucleotide-bind-
ing sites. Energy originating from ATP hydrolysis is uti-
lised for the transportation of substances across cell
membranes [13, 14].
It has been demonstrated that P-gp actively
eliminates from the cell cytostatic drugs of vari-
ous therapeutic groups (Table 1) [13, 14]. The si-
lencing of the MDR1 gene coding for P-gp makes
tumour cells sensitive to cytostatic drugs [28]. The
unfavourable significance of P-gp expression has
been documented in numerous tumours treated
by chemotherapy (Table 1), including ovarian can-
cers [13, 32, 47].
An interesting trend in P-gp-linked studies was
started by the study of Patel et al. [35], who described
an experiment in which cell lines of rat kidney me-
sangium were transfected with the gene coding for
cyclooxygenase-2 (COX-2). The transfection with
COX-2 was found to be followed by a significant
increase in P-gp expression. In our studies, performed
on sections from ovarian cancers [47] or breast can-
cers [51], a strong positive correlation was detected
between expressions of COX-2 and P-gp. The reports
may carry significant clinical implications. The au-
thors suggest that the application of economical and
well tolerated drugs which inhibit the activity of COX-2,
such as aspirin or non-steroid anti-inflammatory
drugs, may markedly affect the efficacy of tumour
chemotherapy and also the expression of P-gp.
MRPs
MRP proteins (MDR-related proteins) form
a family of proteins, including MRP1, MRP2, MRP3,
MRP4, MRP5, MRP6, MRP7, MRP8 and MRP9 pro-
teins. In the phenomenon of resistance to cytostatic
drugs the most important role seems to be played
by MRP1-MRP4 proteins [13, 14].
MRP1 (glutathione and glucuronate conjugate
pump and resistance factor for anthracyclines, epi-
opodophyllotoxins, vinca alkaloids and campoth-
ecins) consists of 1531 amino acids. Its sequence
manifests a 15% homology with that of P-gp. The
protein is involved in the transportation of organic
anions. Overexpression of MRP1 is linked to augment-
ed activity of the ATP-dependent transportation of
endogenous glutathione, glucuronate or sulphate
Table 1. Tissue localisation of selected ATP-binding cassette (ABC) transporters, their function and the significance of their
expression in tumour cells
Common name Tissue Chemotherapy substrates Expression described in tumours
PGP/MDR1 Intestine, liver, kidney, Doxorubicin, daunorubicin, vincristine, Ovarian, breast, lung, adrenal, kidney,
placenta, blood-brain barrier vinblastine, actinomycin-D, paclitaxel, liver, colon, pancreas, lymphoma,
docetaxel, etoposide, teniposide, bisantrene neuroblastoma, leukaemia
MRP1 All tissues Doxorubicin, epirubicin, etoposide, Ovarian, oesophagus, gastric, thyroid gland,
vincristine, methotrexate lung, lymphomas, neuroblastoma, leukaemia
MRP2 Liver, kidney, intestine Cisplatin, methotrexate, etoposide, Ovarian, colon, gastric, kidney, lung,
doxorubicin, vincristine, doxorubicin leukaemia
MRP3 Pancreas, kidney, intestine, Etoposide, teniposide, methotrexate, Ovarian, kidney, lung, colon
liver, adrenal glands cisplatin, vincristine, doxorubicin
MRP4 Prostate, testis, ovary, Methotrexate, thiopurines Leukemia
intestine, pancreas, lung
BCRP Brain, monocytes Cisplatin, doxorubicin, daunorubicin, Ovarian, colon, liver, lung, breast, placenta,
etoposid, epirubicin, mitoxantrone, leukaemia
topotecan, SN-38
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conjugates [13, 14]. The protein is present in the
muscles, lungs, spleen, urinary bladder, gallbladder
and the suprarenal cortex. In the case of tumours
the activity results in a lowered intracellular accu-
mulation of cytostatic drugs, leading to resistance
to these drugs (Table 1). Expression of the protein
has been demonstrated in numerous tumours (Ta-
ble 1) [13, 14]. In the case of ovarian cancers some
reports have described expression of MRP1. Yakirev-
ich et al. [60] failed to demonstrate a relationship
between MRP1 expression and the survival of ovari-
an cancer patients. They documented a positive cor-
relation between expression of MRP1 and the ex-
pression of other proteins linked to resistance to cy-
tostatic drugs, such as p53 and BCL-2. Arts et al. [2]
were also unable to show a relationship between
expression of MRP1 and overall survival time, pro-
gression-free time and clinical response. On the oth-
er hand, they documented a positive correlation
between expression of MRP1 and expressions of
MRP2 and P-gp. Similarly, Katsaros et al. [25] de-
tected a positive correlation between expressions of
MRP1 on the one hand and P-gp and MRP2 on the
other but found no relationship with the clinical re-
sponse to chemotherapy.
MRP2 (canalicular efflux pump for amphipathic
anions and resistance factor for anticancer agents),
also termed cMOAT (canalicular multispecific organic
anion transporter) is responsible for bilirubin glucu-
ronate transportation from hepatocyte to biliary
canaliculi. Mutation of the gene coding for MRP2 is
linked to pathogenesis of Dubin-Johnson’s syndrome.
In physiological conditions the protein is manifest
mainly in the liver, kidneys, intestines and central
nervous system, in which it participates in the for-
mation of the blood/brain barrier. Expression of the
protein has been reported in numerous tumours
(Table 1). Its activity is mainly linked to resistance to
cisplatin (Table 1) and it should thus play a signifi-
cant role in predicting the clinical response to che-
motherapy in ovarian cancer [13, 14, 27, 30, 36, 52].
Studies on the relationship between the expression
of MRP2 at the level of mRNA in ovarian cancers and
clinical data have demonstrated no prognostic or pre-
dictive value in estimations of MRP2 expression [32].
Gumiński et al. [15] showed that immunohistochem-
ical detection of MRP2 expression in ovarian cancer
demonstrated a variable intracellular localisation of
the protein. The authors detected no relationship
between expression of MRP2 and the clinical data of
the patients studied. We have documented that
MRP2 may be present not only in plasma membrane,
but also in the nuclear envelope of ovarian cancer
cells (Fig. 1A, B, C) [50]. Ovarian cancer cases with
nuclear MRP2 expression demonstrated a significantly
shorter overall survival time. Silencing of the MRP2
coding gene using a multiribozyme resulted in a de-
creased expression of mRNA and nuclear expression
of the protein (Fig. 1D) [28].
Expression of other MRP proteins in ovarian can-
cers has been poorly recognised or has not hitherto
been studied.
BCRP
Breast cancer resistance protein (BCRP) belongs
to subfamily G of the ABC transporters. Expression
of BCRP has been described in several tumours
(Table 1). Overexpression of BCRP results in resis-
tance to a broad range of antineoplastic drugs
[1, 40, 61]. Jia et al. [24] demonstrated that BCRP is
responsible for the resistance of ovarian cancer cells
to topotecan.
APOPTOSIS
Platinum analogues represent the drugs most fre-
quently applied in the therapy of ovarian cancer. The
mechanism of action of cisplatin and of other plati-
num analogues involves binding drug molecules to
DNA (the formation of so-called DNA adducts). Cells
may react to the formation of such adducts in vari-
ous ways, depending upon the efficacy of their reg-
ulatory systems, proliferative activity and the num-
ber of adducts formed. One of the possible cellular
reactions involves DNA repair and the other mobili-
sation of the process of cell apoptosis. The efficien-
cy of a therapy incorporating platinum analogues
thus reflects the efficacy of the mechanisms which
control apoptosis. The best recognised apoptosis
regulators of predictive value in ovarian cancers are
p53, p21, p27 and BCL-2 [42, 55, 57].
p53
The most frequent genetic alteration in ovarian
cancers involves mutations of the P53 gene. P53 is
a suppressor gene and is localised on chromosome
17p13.1. p53 protein is a transcription factor which
may induce or inhibit expression of several genes,
including MDM2, Bax, BCL-2, Fas. In this way, p53
controls functions important for cell life: prolifera-
tion, apoptosis and DNA repair. If a cell contains
mutated p53, the process of switching on apoptosis
becomes less probable: tumour cells with mutated
p53 continue to proliferate despite numerous lesions
to DNA, induced by cytostatic drugs [26].
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Figure 1. Immunohistochemical localisation of MRP2 expression in the nuclear membrane of: A. Cisplatin-resistant A2780RCIS ovarian car-
cinoma cell line; B. Ovarian carcinoma specimen; C. Western-blot analysis of MRP2 expression in the nuclear fraction of proteins in the cis-
platin-sensitive A2780P ovarian carcinoma cell line and cisplatin-resistant A2780RCIS ovarian carcinoma cell line (GAPDH control, note
stronger reaction intensity in cisplatin-resistant A2780RCIS cells); D. MRP2 expression in the nuclear membrane of: D1. Cisplatin-resistant
A2780RCIS ovarian carcinoma cell line, D2. No reaction in cisplatin-resistant A2780RCIS ovarian carcinoma cell line transfected with multiri-
bozyme directed against MRP2, P-gp and BCRP mRNA [32].
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Mutations of the P53 gene not only play a sig-
nificant role in the pathogenesis of ovarian can-
cers but also in the biology. Tumours with overex-
pression of the p53 protein are less differentiated
and manifest higher proliferative potential and
a more aggressive clinical course [29, 37]. In in vitro
studies cells of lymphoma, ovarian cancer and lung
cancer with a mutated P53 manifest a much lower
sensitivity to cisplatin than do cells carrying no such
mutation. Transfection of the mutated cells with
the normal P53 gene increased their sensitivity to
cisplatin [11]. Numerous studies have demonstrat-
ed the unfavourable prognostic and predictive sig-
nificance of p53 overexpression in ovarian cancers
related to their response to treatment with cispl-
atin [12, 19, 20]. It is beyond doubt that p53 is
one of the most important molecular prognostic
and predictive indices in ovarian cancers. Immu-
nocytochemical estimation of p53 protein expres-
sion seems to carry the highest prognostic and pre-
dictive value.
Proteins of the BCL-2 family
One of the earliest processes to develop in apop-
tosis involves release of proteins such as apoptosis
inducing factor (AIF) and cytochrome C from the in-
termembranous space of mitochondria to the cyto-
plasm. The release of cytochrome C from the mito-
chondria remains under the strict control of proteins
from the BCL-2 family. Some of the proteins, such as
BCL-2, BCL-xL, MCL-1 and BCL-W, prevent apoptosis,
while others, such as BAX, BCL-xS, BAK, BAD, BIK and
BID, stimulate the process [6, 26, 55].
Augmented expression of proteins of the BCL-2
family, which inhibit apoptosis, represents an un-
favourable predictive factor in therapy with platinum
analogues. Many authors have shown the unfavour-
able predictive value of BCL-2 expression in ovarian
cancers [42]. Verkis et al. [54] performed a statisti-
cal analysis of the generally available data on ex-
pression of 1416 genes in 60 cell lines (http://
dtp.nci.nih.gov) and of their sensitivity to four dis-
tinct platinum analogues: cisplatin, carboplatin, ox-
aliplatin and tetraplatin. The studies demonstrated
that resistance to cisplatin and carboplatin was par-
alleled to a high degree by overexpression of BCL-xL.
Williams et al. [58] described BCL-xL expression in
biopsies originating from 28 cases of ovarian cancer.
The authors showed that overexpression of BCL-xL
was typical for patients with a shorter relapse-free
survival. The results, however, require confirmation
on more extensive material.
TRAPPING OF DRUGS IN CELLS
Numerous investigations have demonstrated that
cytostatic drugs may be bound to proteins or glu-
tathione in neoplastic cells. An example of such bind-
ing is provided by the binding of platinum analogues
to metallothioneins.
Metallothioneins (MTs) are low molecular
weight proteins (6–7 kDa) whose chains are com-
posed of 61 or 62 amino acids. Typically, they con-
tain multiple cysteine residues and few aromatic
amino acids. MTs are thought to mediate several
functions, including control of the levels of indis-
pensable trace elements (such as zinc and copper),
alleviation of the toxic effects of cadmium and mer-
cury and protection of cells from oxidative stress [17].
Numerous reports have been published on MT ex-
pression in ovarian cancers [33, 46, 48, 59]. Opin-
ions diverge on the relationship between MT expres-
sion and clinical course in ovarian cancer patients
treated with various chemotherapeutic protocols
based on platinum analogues.
Another example of the intracellular binding of
drugs involves their conjugation with glutathione. The
reaction is catalysed by glutathione transferases.
Glutathione S-transferases (GSTs) catalyse con-
jugation of reduced glutathione with a variety of elec-
trophilic xenobiotics and also play a role in the deg-
radation of lipid peroxidation products [5]. The re-
sulting glutathione adducts have increased solubili-
ty and can then either be excreted or further meta-
bolised.
The GST-pi isoform is best recognised and mani-
fests a close relationship with resistance to cytostatic
drugs. A relationship has been suggested between
expression of and resistance to cisplatin, adriamy-
cin, cyclophosphamide and etoposide [5]. However,
the data on relations between expression of GST-pi
and clinical response to cisplatin therapy are diver-
gent: in several studies expression of GST-pi has been
noted to correlate with a less favourable response
to cisplatin [8, 41, 48], whereas no such relationship
can be detected in other investigations [22].
HER-2
Human epidermal growth factor receptor (HER-2)
belongs to the group of type I tyrosine kinase recep-
tors for the human epidermal growth factor. The HER-2
gene was found to represent a proto-oncogene. Am-
plification of the HER-2 gene plays a significant role
in the process of neoplastic transformation [43].
Amplification and/or overexpression of HER-2 deve-
lops in 10–50% of cases of ovarian cancer and is linked
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to a more aggressive clinical course of the disease.
A relationship has also been demonstrated between
HER-2 overexpression and resistance to cisplatin. In
in vitro studies tumour cells transfected with the HER-2
gene became resistant to cisplatin. Application of
emodin, a tyrosine kinase inhibitor, and of antibodies
specific for HER-2 was also found to augment the
sensitivity of cells to cisplatin. Chemotherapy with cis-
platin and cyclophosphamide was demonstrated to
extend significantly the survival of patients with ovari-
an cancer who manifested a low expression of HER-2
but failed to exert such an effect in cases with over-
expression of the protein [42, 55, 57].
TOPOISOMERASE 1A
Topoisomerases (TOP) are nuclear enzymes which
transiently break und unwind DNA in the process of
DNA replication and transcription [56]. Augmented
expression of TOP 1A has been described in various
types of tumours, including ovarian cancers [21, 34].
The protein provides a target for the group of anti-
neoplastic drugs termed campothecins (topotecan
and irrotecan), frequently used in ovarian cancers [56].
Expression of TOP 1A has been documented as a sig-
nificant predictive index in campothecin-based ther-
apy [39]. We have shown that ovarian cancer cases
with augmented expression of TOP 1A demonstrat-
ed a significantly shorter overall survival time [49].
It should be noted that topotecan has not been used
in the group of patients studied. The observations
indicate that in cases with augmented expression of
TOP 1A application of topotecan should be consid-
ered, as it might favourably change the prognosis in
this group of patients.
MICROARRAY ANALYSIS OF
TREATMENT RESPONSE
In the above sections various mechanisms have been
described which may be responsible for resistance of
tumour cells to cytostatic drugs. Despite the close rela-
tionship between expression of the selected proteins
and the phenomenon of in vitro resistance to cytostat-
ic drugs, the data are not so unequivocal in cases of
clinical studies. This may reflect the complexity of the
resistance to cytostatic drugs with the effect that de-
termination of individual variables in clinical cases,
which are frequently subjected to chemotherapy with
the use of several anti-neoplastic agents, often pro-
vides no clinically significant information. Another rea-
son for the phenomenon may involve the function of
distinct mechanisms, so far unrecognised, responsible
for resistance to chemotherapy.
Nowadays, high hopes for more detailed recog-
nition of the phenomenon of resistance to cytostat-
ic drugs and, consequently, for the design of an ap-
propriate predictive clinical test have been placed in
DNA microarrays. This technique allows several thou-
sand genes to be examined in a single sample of
expression. DNA microarrays thus have the poten-
tial for the “blind” examination of several biological
phenomena, including MDR. Nevertheless, the tech-
nique raises several problems, including that of per-
forming a reliable analysis of such extensive data.
The first investigations performed with the use of
DNA microarrays have already brought to light new
data on the MDR phenomenon [63].
In our study the sensitivity was tested of 30 dif-
ferent cell lines, including four cell lines of ovarian
cancer (ES-2, FU-OV-1, OVCAR3 and SKOV-3), to the
11 most frequently applied cytostatic agents in their
clinically relevant concentrations [16]. Subsequent-
ly, using Affymetrix U133A arrays, the expression pro-
files of 24,000 genes were tested. For the resistance
to each chemotherapy agent an individual predic-
tion profile was constructed, containing 42 to 516
genes. The overall accuracy of the predictions in
a leave-one-out cross validation was 81.7%. A list
was drawn up identifying the top 67 multidrug re-
sistance candidate genes associated with resistance
to at least four anticancer agents. Hartmann et al. [18]
described analysis of gene expression using cDNA
microarrays containing 30,721 genes in 79 prima-
ry surgically resected tumours from women with
advanced-stage, high-grade epithelial ovarian can-
cer. A 14-gene predictive model was developed and
subsequently tested. This model correctly predicted
the outcome of 24 of the 28 test samples (86% ac-
curacy) with a 95% positive predictive value for ear-
ly relapse. Spentos et al. [45] in similar studies de-
scribed a list of 115 genes of independent prognos-
tic significance in ovarian cancer. The authors also
provided a list of 93 genes to enable the pathologi-
cal response in epithelial ovarian cancers to be de-
fined [44]. Jazaeri et al. [23] listed 178 genes, the
expression of which differed between ovarian can-
cer post-chemotherapy samples and primary ovari-
an tumours. Duan et al. [9] examined three cell lines
primarily sensitive to paclitaxel and their variants,
which were resistant to the agent. The resistant cell
lines differed from the sensitive ones in expression
of, respectively, 790, 689 and 964 genes. Summing
up, the reports published to date have listed tens to
hundreds of new genes which are typical of cases or
cell lines resistant to cytostatic drugs.
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THE EPIGENETICS OF
THE MDR PHENOMENON
In recent years numerous reports have appeared
which suggest that disturbed methylation of the so-
called CpG DNA islands represents one of the key
processes responsible for neoplastic transformation.
In promoter regions of structural genes the CpG is-
lands are present in high numbers. Methylation of
cytosine induces silencing of a given gene. In tumour
cells a significant decrease is noted in global DNA
methylation, which results in chromosomal instabil-
ity. The exception involves promoter regions of sup-
pressor genes which, in contrast, are hypermethy-
lated [10]. Inhibitors of DNA methyltransferase are
tested as potential anti-neoplastic drugs [31].
In the period 2003–2006 reports appeared de-
scribing the relation between aberrant methylation
of individual genes (MDR1, RASSFIA, HICI, MGMT)
and the development of the resistance of tumour
cells to cytostatic drugs. In the light of the fact that
methylation aberrations specific to tumours pertain
to a significant extent to the genes responsible for
the response to cytostatic drugs (genes linked to
the response to DNA injury and genes controlling
cell cycle apoptosis for instance), the conclusion
can be drawn that aberrant methylation also pro-
vides grounds for the resistance to cytostatic drugs
[31, 38, 53]. The hypothesis is additionally strength-
ened by the fact that DNA methyltransferase inhibi-
tors make tumour cells sensitive to some drugs (the
corresponding literature data pertain mainly to cis-
platin) [4].
CONCLUSIONS
The phenomenon of resistance to cytostatic drugs
represents a very complex phenomenon and one that
remains incompletely recognised. As a result, no pre-
dictive panel has yet been designed which could be
implemented in routine pathological diagnosis of sen-
sitivity to individual cytostatic drugs in a given pa-
tient. The potential for individual prediction of sensi-
tivity to cytostatic drugs is of great importance, since
in the first lapse of chemotherapy it enables the ap-
plication of drugs which are ineffective or poorly ef-
fective in tumour cells to be avoided. The application
of such drugs results in a growing resistance to che-
motherapy in the tumour cells (Fig. 2). When it is tak-
en into account that MDR represents a cross-reactive
phenomenon, such cases may be linked to a signifi-
cantly decreased probability of reaction to drugs, even
to agents to which a given tumour was primarily sen-
sitive, following the alteration of therapeutic scheme.
In cases of ovarian cancer tests to determine the
expression of p53, BCL-2 and other apoptosis regu-
lators have hitherto had the greatest predictive sig-
nificance, while the estimation of HER-2, P-gp and
the expression of other ABC-transporters are associ-
ated with much greater divergence.
Studies using DNA microarrays have brought new
insights into the phenomenon of MDR. The reports
so far published have listed from tens to hundreds
of genes which are typical of cases or cell lines resis-
tant to cytostatic drugs. It is surprising that the lists
seldom incorporate genes which have already been
recognised as responsible for MDR.
Summing up, the studies performed to date
have failed to result in a test which would enable
sensitivity or resistance to individual cytostatic
agents to be predicted on an individual basis. Such
a test cannot rely on the estimation of individual
protein expression. It is highly likely that a test to
predict the response to chemotherapy in ovarian can-
cers and other tumours would involve estimation
of the expression of more than ten or a hundred
Figure 2. Immunohistochemical localisation of metallothionein
expression in: A. Cisplatin-resistant A2780RCIS ovarian carcino-
ma cell line; B. Cisplatin-resistant A2780RCIS ovarian carcinoma
cell line after 72 hours of exposure at 33.3 µM of cisplatin.
72 hours exposure at
33.3 mM of cisplatin
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genes and would include the genes which are rec-
ognised at present as responsible for MDR as well
as new genes selected using DNA microarrays and
pangenomic studies on aberrations in DNA me-
thylation.
REFERENCES
1. Allen JD, Schinkel AH (2002) Multidrug resistance and
pharmacological protection mediated by the breast
cancer resistance protein (BCRP/ABCG2). Mol Cancer
Ther, 1: 427–434.
2. Arts HJG, Katsaros D, de Vries EGE, Massobrio M, Genta F,
Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL,
Willemese PHB, van der Zee AGJ, Suurmeijer AJH (1999)
Drug resistance-associated markers P-glycoprotein,
multidrug resistance-associated protein 1, multidrug
resistance-associated protein 2, and lung resistance
protein as prognostic factors in ovarian carcinoma. Clin
Cancer Res, 5: 2798–2805.
3. Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC,
Chmiel JS, Zuber K, Karnell LH, Winchester DP (1993)
National survey of ovarian carcinoma. 1. A patient care
evaluation study of the Amercian College of Surgeons.
Cancer, 71: 1629–1638.
4. Baker E, El-Osta A (2003) The rise of DNA methylation
and the importance of chromatin on multidrug resis-
tance in cancer. Exp Cell Res, 290: 177–194.
5. Beeghly A, Katsaros D, Chen H, Fraccholi S, Zhang Y,
Massorbio M, Risch H, Jones B, Yu H (2006) Glutathione
S-transferase polymorphisms and ovarian cancer treat-
ment and survival. Gynecol Oncol, 100: 330–337.
6. Brown JM, Attardi LD (2005) The role of apoptosis in
cancer development and treatment response. Nat Rev
Cancer, 5: 231–237.
7. Cannistra SA (2004) Cancer of the ovary. N Engl J Med,
351: 2519–29.
8. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD
(2003) Glutathione S-transferase pi amplification is
associated with cisplatin resistance in head and neck
squamous cell carcinoma cell lines and primary tumors.
Cancer Res, 63: 8097–8102.
9. Duan Z, Lamendola DE, Cuan Y, Yusuf RZ, Seiden M
(2005) Description of paclitaxel resistance-associated
genes in ovarian and breast cancer cell lines. Cancer
Chemother Pharmacol, 55: 277–285.
10. Esteller M (2005) Aberrant DNA methylation as a can-
cer-inducing mechanism. Annu Rev Pharmacol Toxi-
col, 45: 629–656.
11. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Ber-
naudin JF, Riou G, Benard J (1996) Cisplatin-induced
apoptosis and p53 gene status in a cisplatin-resistant
human ovarian carcinoma cell line. Int J Cancer, 68:
67–74.
12. Ferrandina G, Fagotti A, Salerno MG (1999) p53 over-
-expression is associated with cytoreduction and re-
sponse to chemotherapy in ovarian cancer. Br J Can-
cer, 81: 733–740.
13. Gottesman MM, Fojo T, Bates SE (2002) Multidrug re-
sistance in cancer: role of ATP-dependent transport-
ers. Nature Rev, 2: 48–58.
14. Gottesman MM (2002) Mechanisms of cancer drug
resistance. Annu Rev Med, 53: 615–27.
15. Gumiński AD, Balleine RL, Chiew Y-E, Webster LR, Tap-
ner M, Farrel GC, Harnett PR, DeFazio A (2006) MRP2
(ABCC2) and cisplatin sensitivity in hepatocytes and hu-
man ovarian carcinoma. Gynecol Oncol, 100: 239–246.
16. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R,
Dietel M, Lage H (2006) Resistance prediction profile
for eleven anticancer agents at clinical concentrations
based on the gene expression pattern of thirty cell lines.
Int J Cancer, 118: 1699–1712.
17. Hamer DH (1986) Metallothionein. Annu Rev Biochem,
55: 913–951.
18. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Ger-
shenson D, Bast RC, Stec J, Iatchouk N, Smith DI, Ross JS,
Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA,
Damokosh AI (2005) Gene expression profiles predict
early relapse in ovarian cancer after platinum-paclitaxel
chemotherapy. Clin Cancer Res, 11: 2149–2155.
19. Havrilesky L, Darcy KM, Hamdan H (2003) Prognostic
significance of p53 mutation and p53 overexpression
in advanced epithelial ovarian cancer: A Gynecologic
Oncology Group Study. J Clin Oncol, 21: 3814–3825.
20. Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N,
Igarashi M, Tachibana M, Nagasue N (1997) Overex-
pression of metallothionein correlates with chemore-
sistance to cisplatin and prognosis in esophageal can-
cer. Lab Invest, 54: 342–347.
21. Husain I, Mohler JL, Seigler HF, Besterman JM (1994)
Elevation of topoisomerase I messenger RNA, protein,
and catalytic activity in human tumors: demonstration
of tumor-type specificity and implications for cancer
chemotherapy. Cancer Res, 54: 539–546.
22. Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N,
Watari H, Shimizus M, Minanami H, Sakuragi N (2003)
Multivariate analysis for prognostic significance of his-
tologic subtype, GST-pi, MDR-1, and p53 in stages II–IV
ovarian cancer. Int J Gynecol Cancer, 13: 776–784.
23. Jazaeri AA, Awtrey CS, Chandramouli GVR, Chuang YE,
Khan J, Sotiriou C, Aprelkova O, Yee CJ, Zorn KK, Birrer MJ,
Barrett JC, Boyd J (2005) Gene expression profiles as-
sociated with response to chemotherapy in epithelial
ovarian cancer. Clin Cancer Res, 11: 6300–6310.
24. Jia P, Wu S, Li F, Xu Q, Wu M, Chen G, Liao G, Wang S,
Zhou J, Lu Y, Ma D (2005) Breast cancer resistance
protein-mediated topotecan resistance in ovarian can-
cer cells. Int J Gynecol Cancer, 15: 1042–1048.
25. Katsaros D, Fracchioli S, Arts HJ, de Vries EG, Danese S,
Richiardi G, Arisio R, Gordini G, van der Zee AG, Suur-
meijer AJ, Massobrio M (1999) Expression and prog-
nostic value of the drug resistance markers P-gp, Mrp1,
Mrp2, and Lrp in ovarian carcinoma. Minerva Ginecol,
51: 463–470.
26. Kawiak J, Zabel M (2002) Seminaria z cytofizjologii.
Urban & Partner, Wrocław.
27. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ,
Juijn JA, Baas F, Borst P (1997) Analysis of expression
of cMOAT (MRP2), MRP3, MRP4, and MRP5, homo-
logues of the multidrug resistance-associated protein
gene (MRP1), in human cancer cell lines. Cancer Res,
57: 3537–3547.
293
P. Surowiak, Prediction in ovarian cancers
28. Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-
-resistant phenotypes by an autocatalytic multitarget
multirybozyme directed against the transcripts of the
ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol
Ther, 11: 1393–1398.
29. Kupryjanczyk J, Bell D, Dimeo D (1995) p53 gene ana-
lysis of ovarian bordeline tumors and stage I carcino-
mas. Hum Pathol, 26: 387–392.
30. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H
(2003) Overexpression of cMOAT (MRP2/ABCC2) is as-
sociated with decreased formation of platinum-DNA
adducts and decreased G2-arrest in melanoma cells
resistant to cisplatin. J Invest Dermatol, 121: 172–176.
31. Lyko F, Brown R (2005) DNA methyltransferase inhib-
itors and the development of epigenetic cancer thera-
pies. J Natl Cancer Inst, 97: 1498–1506.
32. Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA
expression of MDR1/P-glycoprotein, DNA-topoi-
somerase I, and MRP2 in ovarian carcinoma patients:
correlation with chemotherapeutic response. Gynecol
Oncol, 94: 152–160.
33. McCluggage WG, Strand K, Abdulkair A (2002) Immu-
nohistochemical localization of metallothionein in be-
nign and malignant epithelial ovarian tumours. Int J
Gynecol Cancer, 12: 62–65.
34. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D,
van der Zee AG, Kaye SB, Brown R, Keith WN (1994)
Topoisomerase I and II activity in human breast, cer-
vix, lung and colon cancer. Int J Cancer, 59: 607–611.
35. Patel VA, Dunn MJ, Sorokin A (2002) Regulation of
MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol
Chem, 227: 38915–38920.
36. Perego P, Gatti L, Righetti SC, Bereta GL, Carenini N,
Corna E, Bo LD, Tineli S, Cloangelo D, Leone R, Apos-
toli P, Lombardi L, Beggiolini G, Piazzoni L, Zunino F
(2003) Development of resistance to a trinuclear pla-
tinum complex in ovarian carcinoma cells. Int J Can-
cer, 105: 617–624.
37. Plisiecka-Hałasa J, Karpińska G, Szymańska T,
Ziółkowska I, Mądry R, Timorek A, Dębniak J, Ułańska M,
Jedryka M, Chudecka-Głaz A, Klimek M, Rembiszew-
ska A, Kraszewska E, Dybowski B, Markowska J, Emer-
ich J, Płużańska A, Goluda M, Rzepka-Górska I, Urbański K,
Zieliński J, Stelmachów J, Chrabowska M, Kupryjań-
czyk J (2003) P21WAF1, p27KIP1, TP53 and C-MYC anal-
ysis in 204 ovarian carcinomas treated with platinum-
based regimens. Annals Oncol, 14: 1078–1085.
38. Qiu YY, Mirkin BL, Dwivedi RS (2005) Inhibition of DNA
methyltransferase reverses cisplatin induced drug re-
sistance in murine neuroblastoma cells. Cancer Det
Prev, 29: 456–463.
39. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W,
Santana VM, Houghton PJ (2000) Clinical use of to-
poisomerase inhibitors in anticancer treatment. Med
Ped Oncol, 35: 382–402.
40. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004)
ABCG2 — a transporter for all seasons. FEBS Letters,
567: 116–120.
41. Satoh T, Nishida M, Tsunoda H, Kubo T (2001) Expression
of glutathione S-transferase pi (GST-pi) in human ovarian
tumors. Eur J Obstet Gynecol Reprod Biol, 96: 202–208.
42. Siddik ZH (2003) Cisplatin: mode of cytotoxic action
and molecular basis of resistance. Oncogene, 22: 7265–
–7279.
43. Slamon D, Clark G (1988) Amplification of C-ERB-B2
and agressive breast tumors? Science, 240: 1795–1798.
44. Spentoz D, Levine DA, Kolia S, Out H, Boyd J, Liber-
mann TA, Cannistra SA (2005) Unique gene expres-
sion profile based on pathologic response in epithelial
ovarian cancer. J Clin Oncol, 23: 7911–7917.
45. Spentoz D, Levine DA, Ramoni MF, Joseph, M, Gu X,
Boyd J, Lbermann TA, Cannistra SA (2004) Gene ex-
pression signature with independent prognostic sig-
nificance in epithelial ovarian cancer. J Clin Oncol, 22:
4700–4710.
46. Surowiak P, Kaplenko I, Spaczyński M, Zabel M (2003)
Expression of metallothionein (MT) and intensity of
proliferation in ovarian cancers treated with cisplatin
and paclitaxel. Fol Morphol, 62: 493–495.
47. Surowiak P, Materna V, Denkert C, Kaplenko I,
Spaczynski M, Dietel M, Zabel M, Lage H (2006)
Significance of cyclooxygenase 2 and MDR1/P-glyco-
protein coexpression in ovarian cancers. Cancer Let-
ters, 235:272–280.
48. Surowiak P, Materna V, Kaplenko I, Spaczynski M,
Dietel M, Lage H, Zabel M (2005) Augmented expres-
sion of metallothionein and glutathione S-transferase
pi as unfavorable prognostic factors in cisplatin-treat-
ed ovarian cancer patients. Virchows Archiv, 447: 626–
–633.
49. Surowiak P, Materna V, Kaplenko I, Spaczynski M,
Dietel M, Lage H, Zabel M (2006) Topoisomerase 1A,
HER/2neu and Ki67 expression in paired primary and
relapse ovarian cancer tissue samples. Histol Histo-
pathol, 25: 131–139.
50. Surowiak P, Materna V, Kaplenko I, Spaczyński M,
Dolińska-Krajewska B, Gębarowska E, Dietel M,
Zabel M, Lage H (2006) ABCC2 (MRP2, cMOAT) can
be localized in the nuclear membrane of ovarian carci-
nomas and correlates with resistance to cisplatin and
clinical outcome. Clin Cancer Res [in press].
51. Surowiak P, Materna V, Matkowski R, Szczuraszek K,
Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C,
Zabel M, Lage H (2005) Relationship between cycloox-
ygenase 2 and P-glycoprotein expressions in invasive
breast cancers and their prognostic significance. Breast
Cancer Res, 7: R862–R870.
52. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T,
Kawakami M, Kagotani K, Okumura K, Akiyama S,
Kuwano M (1996) A human canalicular multispecific
organic anion transporter (cMOAT) gene is overex-
pressed in cisplatin-resistant human cancer cell lines
with decreased drug accumulation. Cancer Res, 56:
4124–4129.
53. Teodoridis JM, Strathdee G, Plumb JA, Brown R (2004)
CpG-island methylation and epigenetic control of re-
sistance to chemotherapy. Biochem Soc Transactions,
32: 916–917.
54. Verkis A, Meynard D, Haaz M-C, Bayssas M, Bonnet J,
Robert J (2004) Molecular determinants of the cyto-
toxicity of platinum compounds: the contribution of
in silico research. Cancer Res, 64: 356–362.
294
Folia Morphol., 2006, Vol. 65, No. 4
55. Wang D, Lippard SJ (2005) Cellular processing of plat-
inum anticancer drugs. Nature Reviews. Drug Discov-
ery, 4: 307–320.
56. Wang JC (2002) Cellular roles of DNA topoisomeras-
es: a molecular perspective. Nat Rev Mol Cell Biol, 3:
430–440.
57. Wernyj RP, Morin PJ (2004) Molecular mechanisms of
platinum resistance: still searching for the Achilles’ heel.
Drug Resistance Updates, 7: 227–232.
58. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S,
Hu YY, Liu R (2005) Expression of Bcl-xL in ovarian car-
cinoma is associated with chemoresistance and recur-
rent disease. Gynecol Oncol, 96: 287–295.
59. Wirgley E, Verspaget HW, Jayson GC, McGown AT
(2000) Metallothionein expression in epithelial ovari-
an cancer: effect of chemotherapy and prognostic sig-
nificance. J Cancer Res Clin Oncol, 126: 717–721.
60. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O,
Resnick MB (2006) Multidrug resistance-related
phenotype and apoptosis-related protein expression
in ovarian serous carcinomas. Gynecol Oncol, 100:
152–159.
61. Yoh K, Ishii G, Yokose, T, Minegishi Y, Tsuta K, Goto
K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004)
Breast cancer resistance protein impacts clinical out-
come in platinum-based chemotherapy for ad-
vanced non-small cell lung cancer. Clin Cancer Res,
10: 1691–1697.
62. Zabel M, Kaczmarek A, Ramlau R, Matecka-Nowak M
(1991) Rola P-glikoproteiny w wielolekowej oporności
nowotworów na cytostatyki. Nowotwory, 41: 32–45.
63. Zasławski R, Surowiak P, Zabel M (2005) Classical and
novel molecular prognostic factors in ovarian cancers.
Pol Merk Lek, 114: 105–111.
